This article is from the source 'bbc' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at http://www.bbc.co.uk/news/uk-wales-32917141

The article has changed 2 times. There is an RSS feed of changes available.

Version 0 Version 1
Acelarin cancer drug impact hope 'remarkable' Acelarin cancer drug impact hope 'remarkable'
(35 minutes later)
The potential impact of a new cancer drug invented in Cardiff has been called "remarkable" at the world's biggest gathering of oncologists. The potential impact of a new cancer drug invented in Cardiff has been praised at the world's biggest gathering of oncologists in Chicago.
Designed to stop patients becoming resistant to common therapies, tests have shown Acelarin to be effective in tackling a range of different cancers. Acelarin is designed to stop patients becoming resistant to common therapies in treating cancer of the lung, ovary, breast, colon and pancreas.
The results of first and second phase clinical trials of the drug are being presented in Chicago. Two phases of clinical trials show half of 78 patients responded to treatment.
The treatment was invented in laboratories at Cardiff University. The treatment was invented at Cardiff University and Prof Chris McGuigan said the drug's success was "remarkable".
It was tested on patients who had exhausted all other forms of treatment at London's Hammersmith Hospital.It was tested on patients who had exhausted all other forms of treatment at London's Hammersmith Hospital.
"These were terminal cancer patients, all of whom had solid tumours that were growing," explained Prof Chris McGuigan from Cardiff University."These were terminal cancer patients, all of whom had solid tumours that were growing," explained Prof Chris McGuigan from Cardiff University.
"Seventy-eight patients were given Acelarin - and remarkably half had their disease brought under control; the tumour growth was stopped, and in some cases reversed.""Seventy-eight patients were given Acelarin - and remarkably half had their disease brought under control; the tumour growth was stopped, and in some cases reversed."
Dr Ian Lewis, director of research and policy for Tenovus Cancer Care said: "The great thing about this treatment is that it appears not only to be effective for patients who have become resistant to common therapies but also for patients with a range of different types of cancer. That makes it particularly exciting."Dr Ian Lewis, director of research and policy for Tenovus Cancer Care said: "The great thing about this treatment is that it appears not only to be effective for patients who have become resistant to common therapies but also for patients with a range of different types of cancer. That makes it particularly exciting."
"The fact that it has come from Cardiff showcases a wider trend for some really world class cancer research here in Wales.""The fact that it has come from Cardiff showcases a wider trend for some really world class cancer research here in Wales."
'Bolt-on''Bolt-on'
The drug was particularly effective against gynaecological tumours. In 13 out of 14 patients, the drug achieved disease control - the greatest success rate ever seen at Hammersmith Hospital.The drug was particularly effective against gynaecological tumours. In 13 out of 14 patients, the drug achieved disease control - the greatest success rate ever seen at Hammersmith Hospital.
The third and final round of clinical trials are now being planned and the drug has been licensed to Edinburgh-based pharmaceutical company Nucana for further development.The third and final round of clinical trials are now being planned and the drug has been licensed to Edinburgh-based pharmaceutical company Nucana for further development.
The results are being presented to 30,000 cancer specialists attending the Asco conference in Chicago.The results are being presented to 30,000 cancer specialists attending the Asco conference in Chicago.
Prof McGuigan believes the method his team invented to design the drug could be used more generally in medicinal research.Prof McGuigan believes the method his team invented to design the drug could be used more generally in medicinal research.
It works by adding new compounds to conventional therapies as a 'bolt-on', which helps the drug cut through any resistance the body has built up.It works by adding new compounds to conventional therapies as a 'bolt-on', which helps the drug cut through any resistance the body has built up.
"Many companies have started to adopt this technology, to bolt it on to various drugs and improve them," Prof McGuigan said."Many companies have started to adopt this technology, to bolt it on to various drugs and improve them," Prof McGuigan said.
"I believe that this will change therapies for cancer and viruses forever - and it originated here in the labs in Cardiff.""I believe that this will change therapies for cancer and viruses forever - and it originated here in the labs in Cardiff."